Islet transplantation: Present and future perspectives

Diabetes/Metabolism Reviews

Volumn 14, Issue 4, 1998, Pages 303-313

  Kenyon, Norma Sue ^a   Ranuncoli, Alessandra ^a   Masetti, Michele ^a   Chatzipetrou, Maria ^a   Ricordi, Camillo ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diabetes; Islets; Tolerance; Transplantation

Indexed keywords

15 DEOXYSPERGUALIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; RAPAMYCIN; TACROLIMUS;

AUTOIMMUNITY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GROWTH DISORDER; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LIVER; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT INDICATION;

CLINICAL TRIALS; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; GUANIDINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; TACROLIMUS; TISSUE DONORS;

EID: 0032462398     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199812)14:4<303::AID-DMR243>3.0.CO;2-E     Document Type: Review

References (100)

1. Ricordi C: Human islet cell transplantation: New perspectives for an old challenge. Diabetes Rev and 4(3): 356, 1996.
2. Shield JPH, and Baum JD: Advances in childhood onset diabetes. Arch Dis Child 78 391-394, 1998.
3. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L, Marchetti P, Gingerich RL, Jaffe AS, Cryer PE, Anderson CB, and Flye MW: Insulin independence after islet transplantation into a type I diabetic patient. Diabetes 39(4): 515-518, 1990.
4. London NJ: Clinical studies of human islet transplantation: Ann R Coll Surg Engl 78(1): 72, 1996.
5. Scharp DW, Lacy PE, Santiago JV, McCullough C, Weide L, Boyle P, Falqui L, Marchetti P, Ricordi C, Gingerich R, Jaffe A, Cryer P, Hanto D, Anderson C, and Flye MW: Results of our first nine intraportal islet allografts in type I, insulin-dependent diabetic patients. Transplantation 51: 76-85, 1991.
6. Warnock GL, Kneteman NM, Ryan E, Seelis REA, Rabinovitch A, and Rajotte RV: Normoglycemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type I (insulin-dependent) diabetes mellitus. Diabetologia 34: 55-58, 1991.
7. Socci C, Falqui L, Davalli AM, Ricordi C, Braghi S, Bertuzzi F, Maffi P, Secchi A, Gavazzi F, Freschi M, Magistretti P, Socci S, Vignali A, Di Carlo V, and Pozza G: Fresh human islet transplantation to replace pancreatic endocrine function in type I diabetic patients. Acta Diabetol 28: 151-157, 1991.
8. Warnock G, Kneteman NM, Ryan EA, Rabinovitch A, and Rajotte RV: Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type I (insulin-dependent) diabetes mellitus. Diabetologia 35: 89-95, 1992.
9. Alejandro R, Burke G, Shapiro ET, Strasser S, Nery J, Ricordi C, Esquenazi V, Miller J, and Mintz DH: Long-term survival of intraportal islet allografts in type I diabetes mellitus. In Pancreatic Islet Cell Transplantation, Ricordi C, Ed. R.G. Landes, Austin, TX, 1992, pp. 410-413.
10. Ricordi C, Tzakis AG, Carroll PB, Zeng Y, Rilo HLR, Alejandro R, Shapiro R, Fung JJ, Demetris AJ, Mintz DH, and Starzl TE: Human islet transplantation in 22 consecutive cases. Transplantation 53: 407-414, 1992.
11. Bloomgarden ZT: International Diabetes Federation Meeting, 1997, and Metropolitan Diabetes Society of New York Meeting, November 1997. Approaches to treatment and other topics in type 1 diabetes: Genetic heterogeneity of diabetes. Diabetes Care 21(4): 658-665, 1998.
12. Keymeulen B, Ling Z, Gorus FK, Delvaux G, Bouwens L, Grupping A, Hendrieckx C, Pipeleers-Marichal M, Van Schravendijk C, Salmela K, and Pipeleers DG. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: Graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 41: 452-459, 1998.
13. Alejandro R, Lehmann R, Ricordi C, Kenyon NS, Angelico MC, Burke G, Esquenazi V, Nery J, Betancourt AE, Kong SS, Miller J, and Mintz DH: Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 46(12): 1983-1989, 1997.
14. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14): 977-986, 1993.
15. Bretzel RG, Hering BJ, Brendel MD, Schultz AO, Schultz B, and Vietzke R: Insulin independence following islet transplantation in man: A comparison of different recipient categories. International Islet Transplant Registry Newsletter 7: December 1996.
16. Hering BJ, Ernst W, Eckard M, Brandhorst H, Brandhorst D, Jahr H, Grossmann R, Brendel M, Friemann S, Federlin K, and Bredzel RG: Improved survival of single donor islet allografts in IDDM recipients by refined peritransplant management. Diabetes 46(suppl 1): 64A, 1997.
17. Gaya SB, Rees AJ, Lechler RI, Williams G, and Mason PD: Malignant disease in patients with long-term renal transplants. Transplantation 59(12): 1705-1709, 1995.
18. Balistreri WF, Bucuvalas JC, and Ryckman FC: The effect of immunosuppression on growth and development. Liver Transplant Surg 1 (5 suppl 1): 64-73, 1995.
19. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, Husberg BS, Gonwa TA, and Klintmalm GB: Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation 64(12): 1801-1807, 1997.
20. London NJ, Robertson GS, Chadwick DR, Johnson PR, James RF, and Bell PR: Human pancreatic islet isolation and transplantation. Clin Transplant 8(5): 421-459, 1994.
21. Merrell RC, Mahoney ME, Basadonna G, Cobb LB, and Maeda M: Failure of canine islet allografts and autografts with cyclosporine. Surgery 98(2): 324-329, 1985.
22. Tobin BW, Lewis JT, Tobin BL, Rajotte RV, and Finegood DT: Markedly reduced beta-cell function does not result in insulin resistance in islet autografted dogs. Diabetes 41(9): 1172-1181, 1992.
23. Boudreaux JP, McHugh L, Canafax DM, Ascher N, Sutherland DE, Payne W, Simmons RL, Najarian JS, and Fryd DS: The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 44(3): 376-381, 1987.
24. Alejandro R, Feldman EC, Bloom AD, and Kenyon NS: Effects of cyclosporin on insulin and C-peptide secretion in healthy beagles. Diabetes 38(6): 698-703, 1989.
25. Jutte NH, Heyse P, Bruining GJ, Zeilmaker GH, and Weimar W: Effect of cyclosporin A on glucose-induced insulin secretion by isolated human islets of Langerhans. Transplant Proc 19(5): 4152-4153, 1987.
26. Yoshimura N, Matsui S, Hamashima T, and Oka T: Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation 47(2): 356-359, 1989.
27. Tze WJ, Tai J, Cheung S: In vitro effects of FK-506 on human and rat islets. Transplantation 49(6): 1172-1174, 1990.
28. Strasser S, Alejandro R, Shapiro ET, Ricordi C, Todo S, and Mintz DH: Effect of FK506 on insulin secretion in normal dogs. Metabolism 41(1): 64-67, 1992.
29. Ricordi C, Zeng YJ, Alejandro R, Tzakis A, Venkataramanan R, Fung J, Bereiter D, Mintz DH, and Starzl TE: In vivo effect of FK506 on human pancreatic islets. Transplantation 52(3): 519-522, 1991.
30. Rilo HL, Zeng Y, Alejandro R, Carroll PB, Bereiter D, Venkataramanan R, Tzakis AG, Starzl TE, and Ricordi C: Effect of FK506 on function of human islets of Langerhans. Transplant Proc 23(6): 3164-3165, 1991.
31. Viviani GL, Borgoglio MG, Fontana I, Borgoglio A, Nocera A, Leprini A, Comaschi M, Valente U, and Adezati L: Azathioprine decreases insulin secretion in human islets. Transplant Proc 21(1 pt 3): 2714-2716, 1996.
32. Teuscher AU, Seaquist ER, and Robertson RP: Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 43(4): 593-598, 1994.
33. Christiansen E, Andersen HB, Rasmussen K, Christensen NJ, Olgaard K, Kirkegaard P, Tronier B, Volund A, Damsbo P, Burcharth F, et al.: Pancreatic beta-cell function and glucose metabolism in human segmental pancreas and kidney transplantation. Am J Physiol 1993 264(3 Pt 1): E441-E449, 1993.
34. Gores PF, Najarian JS, Stephanian E, Lloveras JJ, Kelley SL, and Sutherland DE: Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 341(8836): 19-21, 1993.
35. Reichenspurner H, Hildebrandt A, Human PA, Boehm DH, Rose AG, Odell JA, Reichart B, and Schlorlemmer HU: 15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 50(2): 181-185, 1990.
36. Hughes SE, and Gruber SA: New immunosuppressive drugs in organ transplantation. J Clin Pharmacol 36(12): 1081-1092, 1996.
37. Arita S, Une S, Ohtsuka S, Atiya A, Kasraie A, Shevlin L, and Mullen Y: Prevention of primary islet isograft nonfunction in mice with pravastatin. Transplantation 65: 1429-1433, 1998.
38. Gores PF, Kaufman DB, and Sutherland DE: New strategies for clinical islet transplantation: The role of purified grafts and immunosuppressive therapy. Ann NY Acad Sci 696: 377-389, 1993.
39. Bottino R, Fernandez LA, Ricordi C, Lehmann R, Tsan MF, Oliver R, and Inverardi L: Transplantation of allogeneic islets of Langerhans in the rat liver: Effects of macrophage depletion on graft survival and microenvironment activation. Diabetes 47(3): 316-323, 1998.
40. McDaniel ML, Kwon G, Hill JR, Marshall CA, and Corbett J: Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 211(1): 24-32, 1996.
41. Suarez-Pinzon WL, Strynadka K, and Rabinovitch A: Destruction of rat pancratic islet betacells by cytokines involves the production of cytotoxic aldehydes. Endocrinology 137(12): 5290-5296, 1996.
42. Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Lakey JR, and Rajotte RV: Human pancreatic islet beta-cell destruction by cytokines involves oxygen free radicals and aldehyde production. J Clin Endocrinol Metab 81(9): 3197-3202, 1996.
43. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrije M, Nieman A, Geller DA, Pipeleers DG, Bendtzen K, and Hellerstrom C: Cytokines suppresss human islet function irrespective of their effects on nitric oxide generation. J Clin Invest 93(5): 1968-1974, 1994.
44. Rabinovitch A, Suarez-Pinzon WL, Strynadka K, Schulz R, Lakey JR, Warnock GL, and Rajotte RV: Human pancreatic islet beta-cell destruction by cytokines is independent of nitric oxide production. J Clin Endocrinol Metab 79(4): 1058-1062, 1994.
45. Kaufman DB, Platt JL, Rabe FI, Dunn DL, Bach FH, and Sutherland DE: Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary non function and classic rejection of islet allografts. J Exp Med 172(1): 291-302 1990.
46. Sutherland DE, Goetz FC, and Sibley RK: Recurrence of disease in pancreas transplants. Diabetes 39(1): 85-87 1989.
47. Jaeger C, Brendel MD, Hering BJ, Eckhard M, and Bretzel RG: Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 46(11): 1907-1910, 1997.
48. Jaeger C, Hering BJ, Dyrberg T, Federlin K, and Bretzel RG: Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin-dependent diabetes mellitus undergoing kidney and islet-after-kidney transplantation. Transplantation 62(3): 424-426, 1996.
49. Sandberg JO, Eizirik DL, and Sandler S: IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immunol 108(2): 314-317, 1997.
50. Casteels K, Waer M, Laureys J, Valckx D, Depovere J, Bouillon R, and Mathieu C: Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic non-obese diabetic mice by a combination of a vitamin D3 analog and cyclosporin. Transplantation 65(9): 1225-1232, 1998.
51. Wang T, Singh B, Warnock GL, and Rajotte RV: Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 41(1): 114-117, 1992.
52. Markmann JF, Jacobson JD, Brayman KL, Kimura H, Barker CF, and Naji A: Prevention of recurrent diabetes in BB rats after islet transplantation by monoclonal antibody therapy. Diabetes 38(suppl 1): 165-167, 1989.
53. Masetti M, Inverardi L, Ranuncoli A, Iaria G, Lupo F, Vizzardelli C, Kenyon NS, Alejandro R, and Ricordi C: Current indications and limits of pancreatic islet transplantation in diabetic nephropathy. J Nephrol 10(5): 245-252, 1997.
54. Stock PG, Ascher NL, Chen S, Field J, Bach FH, and Sutherland DE: Evidence for direct and indirect pathways in the generation of the allo-immune response against pancreatic islets. Transplantation 52(4): 704-709, 1991.
55. Kenyon NS, Strasser S, and Alejandro R: Ultraviolet immunomodulation of canine islets for prolongation of allograft survival. Diabetes 39(3): 305-311, 1990.
56. Alejandro R, Latif Z, Noel J, Shienvold FL, and Mintz DH: Effect of anti-Ia antibodies, culture and cyclosporin on prolongation of canine islet allograft survival. Diabetes 36: 269-273, 1987.
57. Suzuki K, Bonner-Weir S, Hollister-Lock J, Colton CK, and Weir GS: Number and volume of islets transplanted in immunobarrier devices. Cell Transplant 7(1): 47-52, 1998.
58. Prevost PH, Flori S, Collier C, Muscat E, and Holland E: Application of AN69 Hydrogel to islet encapsulation. Ann NY Acad Sci 831: 344-349, 1997.
59. Calafiore R, Basta G, Luca G, Boselli C, Bulfalari A, Giustozzi GM, Gialletti R, and Moriconi F: Transplantation of allogeneic/xenogeneic pancreas islets containing coherent microcapsules in adult pigs. Transplant Proc 30: 482-483, 1998.
60. De Vos P, Hillebrands JL, De Haan BJ, Strubbe JH, and Van Schilfgaarde R: An artificial transplantation site for pancreatic islets. Transplant Proc 30: 484, 1998.
61. Powers AC, Brissova M, Lacik I, Anilkumar AV, Shahrokhi K, and Wang TG: Permeability assessment of capsules for islet transplantation. Ann NY Acad Sci 831: 208-216, 1997.
62. Lanza RP, Sullivan SJ, and Chick WL: Perspectives in diabetes: Islet transplantation with immunoisolation. Diabetes 41(12): 1503-1510, 1992.
63. Hill RS, Cruise GM, Hager SR, Lamberti FV, Yu X, Garufis CL, Yu Y, Mundwiler KE, Cole JF, Hubbell JA, Hegre OD, and Scharp DW: Immunoisolation of adult porcine islets for the treatment of diabetes mellitus: The use of photopolymerizable polyethylene glycol in the conformal coating of mass-isolated porcine islets. Ann NY Acad Sci 31: 831-343, 1997.
64. Monaco AP: Transplantation of pancreatic islets with immunoexclusion membranes. Transplant Proc 25(3): 2234-2236, 1993.
65. Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Moloney MK, Schmehl M, Harris M, et al.: Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343(8903): 950-951, 1994.
66. Kenyon NS, Alejandro R, Mintz DH, and Ricordi C: Islet cell transplantation: Beyond the paradigms. Diabetes Metab Rev 12(4): 361-372, 1996.
67. Waldmann H, and Cobbold S: How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 16: 619-644, 1998.
68. Basadonna GP, Auersvald L, Khuong CQ, Zheng XX, Kashio N, Zekzer D, Minozzo M, Qian H, Visser L, Diepstra A, Lazarovits AI, Poppema S, Strom TB, and Rothstein DM: Antibody mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy. Proc Natl Acad Sci USA 95(7): 3821-3826, 1998.
69. Gainer AL, Korbutt GS, Rajotte RV, Warnock GL, and Elliott JF: Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival. Transplantation 63(7): 1017-1021, 1997.
70. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, Mordes JP, and Rossini AA: Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 92: 9560-9564, 1995.
71. Rossini AA, Parker DC, Phillips NE, Durie FH, Noelle RJ, Mordes JP, and Greiner DL: Induction of immunological tolerance to islet allografts. Cell Transplant 5: 49-52, 1996.
72. Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, Gray GS, Bruce DS, Thistlethwaite JR Jr, and Bluestone JA: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 159(11): 5187-5191, 1997.
73. Zheng XX, Schachter AD, Vasconcellos L, Strehlau J, Tian Y, Sharipo M, Harmon W, and Strom TB: Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. Transplantation 65(11): 1512-1515, 1998.
74. Posselt AM, Barker CF, Tomaszewski JE, Markmann JF, Choti MA, and Naji A: Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 249(4974): 1293-1295, 1990.
75. Charlton B, Auchincloss H Jr, and Fathman CG: Mechanisms of transplantation tolerance. Annu Rev Immunol 12: 707-734, 1994.
76. Stewart FM, Crittenden RB, Lowry PA, Pearson-White S, and Quesenberry PJ: Long-term engraftment of normal and post-5-fluorouracil murine marrow into nonmyeloablated mice. Blood 81(10): 2566-2571, 1993.
77. Ricordi C, Murase N, Rastellini C, Bahboo R, Demetris AJ, and Starzl TE: Indefinite survival of rat islet allografts following infusion of donor bone marrow without cytoablation. Cell Transplant 5(1): 53-55, 1996.
78. Ricordi C, Karatzas T, Nery J, Webb M, Selvaggi G, Fernandez L, Khan FA, Ruiz P, Schiff E, Olson L, Fernandez H, Bean J, Esquenazi V, Miller J, and Tzakis AG: Transplantation 63(1): 7-11, 1997.
79. Selawry HP, Wittington KB, and Bellgrau D: Abdominal intratesticular islet-xenograft survival in rats. Diabetes 38(1): 220-223, 1989.
80. Korbutt GS, Elliott JF, and Rajotte RV: Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46: 317-322, 1997.
81. Korbutt GS, Ao Z, Flashner M, Elliott JF, and Rajotte RV: Coencapsulation of allogeneic islets with allogeneic Sertoli cells prolongs graft survival with systemic immunosuppression. Transplant Proc 30: 419, 1998.
82. Selawry HP, and Cameron DF: Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplant 2(2): 123-129, 1993.
83. Lau HT, Yu M, Fontana A, and Stoeckert CJ Jr: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273(5271): 109-112, 1996.
84. Takeda Y, Gotoh M, Dono K, Nishihara M, Grochowiecki T, Kimura F, Yoshida T, Ohta Y, Ota H, Ohzato H, Umeshita K, Takeda T, Matsura N, Sakon M, Kayagaki N, Yagita H, Okumura K, Miyasaka M, and Monden M: Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabetologia 41: 315-321, 1998.
85. Satake M, Korsgsren O, Ridderstad A, Karlsson-Parra A, Wallgren AC, and Moller E: Immunological characteristics of islet cell xenotransplantation in humans and rodents. Immunol Rev 141: 191-211, 1994.
86. Gill RG: Pancreatic islet xenotransplantation. Autoimmunity 15 (suppl): 18-20, 1993.
87. Butler D: Last chance to stop and think on risks of xenotransplants. Nature 391: 320-325, 1998.
88. Tibell A, and Groth CG: No viral disease after xenotransplantation (letter). Nature 392: 646, 1998.
89. Crowther NJ, Gotfredsen CF, Moody AJ, and Green IC: Immunological and insulin secretory studies on isolated porcine islets of Langerhans. J Endocrinol 126(1): 43-49 1990.
90. Korsgren O, Andersson A, and Sandier S: Pretreatment of fetal porcine pancreas in culture with nicotinamide accelerates reversal of diabetes after transplantation to nude mice. Surgery 113(2): 205-214, 1193.
91. Korsgren O, Jansson L, Eizirik D, and Andersson A: Functional and morphological differentiation of fetal porcine islet-like cell clusters after transplantation into nude mice. Diabetologia 34(6): 379-386, 1991.
92. Chance RE: Amino acid sequences of proinsulins and intermediates. Diabetes 21(2 suppl 2): 461-467, 1972.
93. Pittman K, Thomas J, and Thomas F: Reduction of primary nonfuction in discordant pancreas islet xenografts. Transplant Proc 24: 649-650, 1992.
94. Brayman KL, Morel P, Field MJ, Lloveras JJ, Leventhal J, Nakhleh R, Jessurun J, Platt J, Matas AJ, Najanan JS, Gores PL, and Sutherland DER: A comparison of mice and rats as recipients for canine islet xenografts. Transplant Proc 24: 651-652, 1992.
95. Deng S, Ketchum RJ, Levy MM, Derloff JR, Naji A, White DJG, and Brayman KL: Long-term culture or complement inhibition improves early islet function in dog to rat islet xenotransplantation. Transplant Proc 28: 805-806, 1996.
96. Levine F. Gene therapy for diabetes: strategies for β-cell modification and replacement. Diabetes Met Rev 13(4): 209-246, 1997.
97. Jonasson J, Carlsson L, Edlund T, and Edlund H: Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 373 (6498): 606-609, 1994.
98. Bonner-Weir S: Regulation of pancreatic beta-cell mass in vivo. Recent Prog Horm Res 49: 91-104, 1994.
99. Nielsen JH, Billestrup B, Moldrup Allevato G, Peterson ED, Pederson JA, and Hansen JA: Growth of the endocrine pancreas: The role of somatolactogenic hormones and receptors. Biochem Soc Trans 21(1): 146-149, 1993.
100. Finegood DT, Scaglia L, and Bonner-Weir S: Dynamics of beta-cell mass in the growing rat pancreas: Estimation with a simple mathematical model. Diabetes 44(3): 249-256, 1995.